FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2144227499> ?p ?o ?g. }

• W2144227499 endingPage "294" @default.
• W2144227499 startingPage "287" @default.
• W2144227499 abstract "Prostaglandins (PGs) have numerous cardiovascular and inflammatory effects. Cyclooxygenase (COX), which exists as COX-1 and COX-2 isoforms, is the first enzyme in the pathway in which arachidonic acid is converted to PGs. Prostaglandin E2 (PGE2) exerts a variety of biological activities for the maintenance of local homeostasis in the body. Elucidation of PGE2 involvement in the signalling molecules such as COX could lead to potential therapeutic interventions. Here, we have investigated the effects of PGE2 on the induction of COX-2 in human umbilical vein endothelial cells (HUVEC) treated with interleukin-1beta (IL-1beta 1 ng/ml). COX activity was measured by the production of 6-keto-PGF1alpha, PGE2, PGF2alpha and thromboxane B2 (TXB2) in the presence of exogenous arachidonic acids (10 microM for 10 min) using enzyme immunoassay (EIA). COX-1 and COX-2 protein was measured by immunoblotting using specific antibody. Untreated HUVEC contained only COX-1 protein while IL-1beta treated HUVEC contained COX-1 and COX-2 protein. PGE2 (3 microM for 24h) did not affect on COX activity and protein in untreated HUVEC. Interestingly, PGE2 (3 microM for 24h) can inhibit COX-2 protein, but not COX-1 protein, expressed in HUVEC treated with IL-1beta. This inhibition was reversed by coincubation with forskolin (100 microM). The increased COX activity in HUVEC treated with IL-1beta was also inhibited by PGE2 (0.03, 0.3 and 3 microM for 24h) in a dose-dependent manner. Similarly, forskolin (10, 50 or 100 microM) can also reverse the inhibition of PGE2 on increased COX activity in IL-1beta treated HUVEC. The results suggested that (i) PGE2 can initiate negative feedback regulation in the induction of COX-2 elicited by IL-1beta in endothelial cells, (ii) the inhibition of PGE2 on COX-2 protein and activity in IL-1beta treated HUVEC is mediated by cAMP and (iii) the therapeutic use of PGE2 in the condition which COX-2 has been involved may have different roles." @default.
• W2144227499 created "2016-06-24" @default.
• W2144227499 creator A5038547794 @default.
• W2144227499 creator A5045479052 @default.
• W2144227499 creator A5073679338 @default.
• W2144227499 creator A5090264788 @default.
• W2144227499 date "1999-01-01" @default.
• W2144227499 modified "2023-10-06" @default.
• W2144227499 title "The Induction of Cyclooxygenase-2 in IL-1β-Treated Endothelial Cells is Inhibited by Prostaglandin E₂ through cAMP" @default.
• W2144227499 cites W11380603 @default.
• W2144227499 cites W1563962170 @default.
• W2144227499 cites W1587123510 @default.
• W2144227499 cites W1754684850 @default.
• W2144227499 cites W1974026314 @default.
• W2144227499 cites W1988449214 @default.
• W2144227499 cites W2003897562 @default.
• W2144227499 cites W2012810767 @default.
• W2144227499 cites W2035098716 @default.
• W2144227499 cites W2040495867 @default.
• W2144227499 cites W2045247881 @default.
• W2144227499 cites W2059166883 @default.
• W2144227499 cites W2076776375 @default.
• W2144227499 cites W2078829390 @default.
• W2144227499 cites W2081619402 @default.
• W2144227499 cites W2083372376 @default.
• W2144227499 cites W2085680573 @default.
• W2144227499 cites W2113278990 @default.
• W2144227499 cites W2114918609 @default.
• W2144227499 cites W2157603347 @default.
• W2144227499 cites W2160334816 @default.
• W2144227499 cites W2412029874 @default.
• W2144227499 cites W2952696390 @default.
• W2144227499 doi "https://doi.org/10.1080/09629359990298" @default.
• W2144227499 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1781816" @default.
• W2144227499 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10815617" @default.
• W2144227499 hasPublicationYear "1999" @default.
• W2144227499 type Work @default.
• W2144227499 sameAs 2144227499 @default.
• W2144227499 citedByCount "41" @default.
• W2144227499 countsByYear W21442274992012 @default.
• W2144227499 countsByYear W21442274992013 @default.
• W2144227499 countsByYear W21442274992015 @default.
• W2144227499 countsByYear W21442274992016 @default.
• W2144227499 countsByYear W21442274992017 @default.
• W2144227499 countsByYear W21442274992018 @default.
• W2144227499 countsByYear W21442274992021 @default.
• W2144227499 countsByYear W21442274992022 @default.
• W2144227499 countsByYear W21442274992023 @default.
• W2144227499 crossrefType "journal-article" @default.
• W2144227499 hasAuthorship W2144227499A5038547794 @default.
• W2144227499 hasAuthorship W2144227499A5045479052 @default.
• W2144227499 hasAuthorship W2144227499A5073679338 @default.
• W2144227499 hasAuthorship W2144227499A5090264788 @default.
• W2144227499 hasBestOaLocation W21442274991 @default.
• W2144227499 hasConcept C126322002 @default.
• W2144227499 hasConcept C134018914 @default.
• W2144227499 hasConcept C181199279 @default.
• W2144227499 hasConcept C185592680 @default.
• W2144227499 hasConcept C202751555 @default.
• W2144227499 hasConcept C24998067 @default.
• W2144227499 hasConcept C2777411675 @default.
• W2144227499 hasConcept C2777956040 @default.
• W2144227499 hasConcept C2778078955 @default.
• W2144227499 hasConcept C2779276759 @default.
• W2144227499 hasConcept C2779689624 @default.
• W2144227499 hasConcept C2780664492 @default.
• W2144227499 hasConcept C2781128415 @default.
• W2144227499 hasConcept C55493867 @default.
• W2144227499 hasConcept C71924100 @default.
• W2144227499 hasConcept C86803240 @default.
• W2144227499 hasConcept C98274493 @default.
• W2144227499 hasConceptScore W2144227499C126322002 @default.
• W2144227499 hasConceptScore W2144227499C134018914 @default.
• W2144227499 hasConceptScore W2144227499C181199279 @default.
• W2144227499 hasConceptScore W2144227499C185592680 @default.
• W2144227499 hasConceptScore W2144227499C202751555 @default.
• W2144227499 hasConceptScore W2144227499C24998067 @default.
• W2144227499 hasConceptScore W2144227499C2777411675 @default.
• W2144227499 hasConceptScore W2144227499C2777956040 @default.
• W2144227499 hasConceptScore W2144227499C2778078955 @default.
• W2144227499 hasConceptScore W2144227499C2779276759 @default.
• W2144227499 hasConceptScore W2144227499C2779689624 @default.
• W2144227499 hasConceptScore W2144227499C2780664492 @default.
• W2144227499 hasConceptScore W2144227499C2781128415 @default.
• W2144227499 hasConceptScore W2144227499C55493867 @default.
• W2144227499 hasConceptScore W2144227499C71924100 @default.
• W2144227499 hasConceptScore W2144227499C86803240 @default.
• W2144227499 hasConceptScore W2144227499C98274493 @default.
• W2144227499 hasFunder F4320306650 @default.
• W2144227499 hasIssue "6" @default.
• W2144227499 hasLocation W21442274991 @default.
• W2144227499 hasLocation W21442274992 @default.
• W2144227499 hasLocation W21442274993 @default.
• W2144227499 hasLocation W21442274994 @default.
• W2144227499 hasLocation W21442274995 @default.
• W2144227499 hasOpenAccess W2144227499 @default.
• W2144227499 hasPrimaryLocation W21442274991 @default.
• W2144227499 hasRelatedWork W1995293799 @default.

• next